MedTrace Logo

Improving Blood Pressure in Colorado

NCT00520988 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2012-04-27

No results posted yet for this study

Summary

We will improve hypertension control in Colorado by implementing a population-based intervention using interactive voice response (IVR) technology that will be delivered to patients in three healthcare systems across Colorado (Denver Health and Hospitals \[DH\], VA Colorado Healthcare System \[VA\], and Kaiser Permanente of Colorado \[KPCO\]). Together, these organizations serve over 1 million Coloradans. The IVR-based hypertension program will: 1) reach out to more patients using fewer resources than a traditional patient visit approach, 2) implement evidence based guidelines for therapy, 3) facilitate patients' acquisition of medications by allowing them to order and receive medications at home, and 4) enhance medication adherence using tailored educational and motivational messages.

HYPOTHESES:

1. A sizable population of patients is at high risk for further cardiovascular morbidity and mortality, based on uncontrolled hypertension.
2. An IVR-centered intervention among patients with diagnosed but uncontrolled hypertension is feasible.
3. An IVR-centered intervention plus usual care for these patients improves BP control, compared to usual care alone.

Conditions

Interventions

BEHAVIORAL

Use of telephone-based Interactive Voice Recognition system

Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements

Sponsors & Collaborators

  • US Department of Veterans Affairs

    collaborator FED

  • Denver Health Medical Center

    collaborator OTHER

  • Colorado Health Outcomes Program

    collaborator OTHER

  • Kaiser Permanente

    lead OTHER

Principal Investigators

  • Michael Ho, MD PhD · Denver VA Medical Center

  • Edward Havranek, MD · Denver Health Medical Center

  • David Magid, MD MPH · Kaiser Permanente

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00520988 on ClinicalTrials.gov